Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
From Pfizer Inc.
Via Business Wire
Tickers PFE
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
From Pfizer Inc.
Via Business Wire
Tickers PFE
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
Tickers GMAB PFE
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares First-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Completes Acquisition of Seagen
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Provides Full-Year 2024 Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
From Pfizer Inc.
Via Business Wire
Tickers PFE
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
From Pfizer Inc.
Via Business Wire
Tickers PFE
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
From Pfizer Inc.
Via Business Wire
Tickers PFE
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports Third-Quarter 2023 Results
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.